Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with ...
Dusan Vlahovic’s devastating “high-grade” adductor strain suffered in the recent 2-1 home victory against Cagliari was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback